Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Economic Impact of Dropless Therapy vs Usual Care for Cataract Surgery
NCT03640650Phase 4Terminated
- Sponsor
- PeriPharm
- Start
- Aug 2018
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of triamcinolone and Moxisurge in post-operative inflammation and post-operative infection (2 arms), sponsored by PeriPharm. Primary endpoints: Cataract surgery - related healthcare resource use assessed by number of relevant medications, Cataract surgery - related healthcare resource use assessed by number of medical visits and 4 more. Started Aug 2018; status: terminated.
02
Drugs
triamcinoloneMoxisurge
03
Conditions
post-operative inflammationpost-operative infection
Beyond the preview
Go deeper on NCT03640650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03640650.